Skip to main content

Table 2 Cox univariate and multivariate analysis for disease free survival in the 278 premenopausal breast cancer patients

From: GnRH and LHRgene variants predict adverse outcome in premenopausal breast cancer patients

  Patients Univariate analysis Multivariate analysis
Factor of base model Number Percent HR 95 percent CI P value HR 95 percent CI P value
Age (years)         
   <39 54 24 1.00    1.00   
   40–49 167 60 0.72 0.50–1.06   0.66 0.44–0.98  
   50–59 57 21 0.42 0.23–0.77 0.013 0.35 0.19–0.67 <0.001
Nodal status         
   Negative 134 48 1.00    1.00   
   Positive 144 52 1.90 1.34–2.70 <0.001 3.68 2.11–6.42 <0.001
Histological grade         
   Poor 153 55 1.00    1.00   
   Unknown 59 21 0.51 0.32–0.83   0.54 0.33–0.88  
   Well/moderate 66 24 0.55 0.36–0.85 0.002 0.56 0.35–0.88 0.019
Tumor size         
   ≤2 cm 113 41 1.00    1.00   
   >2 cm 165 59 1.77 1.23–2.54 0.002 1.57 1.07–2.30 0.021
Estrogen receptor status         
   Negative 78 28 1.00    1.00   
   Positive 200 72 0.87 0.60–1.27 0.48 1.01 0.68–1.49 0.96
Adjuvant therapy         
   No 158 57 1.00    1.00   
   Yesa 120 43 1.41 1.01–1.97 0.045 0.41 0.24–0.70 0.001
Factors analyzed         
Carriership         
Non-carriersb    1.00    1.00   
GnRH 16Ser 121 44 1.40 1.00–1.96 0.050 1.32 0.93–1.88 0.12
LHR insLQ 131 47 1.59 1.14–2.23 0.007 1.64 1.16–2.32 0.005
Combined carriership         
Non-carriers 87 31 1.00    1.00   
Only GnRH 16Ser 60 22 1.39 0.84–2.29 0.19 1.24 0.74–2.08 0.42
Only LHR insLQ 70 25 1.59 0.99–2.54 0.055 1.56 0.97–2.51 0.067
LHR insLQ+GnRH16Ser 61 22 2.17 1.36–3.48 0.001 2.14 1.32–3.45 0.002
  1. aOf 120 patients who received adjuvant therapy, 110 received chemotherapy (mainly CMF, n = 101), 4 endocrine therapy, and 6 both; node negatives were not treated. bThe number of GnRH 16Ser non-carriers was 157, and of LHR insLQ non-carriers was 147 patients.